GM
Garrido, M.
3 yayın · 244 atıf · 2023–2025
Yayın
3
Atıf
244
Yıllar
2
Yayınlar
| Başlık | Yıl | Tip | Atıf |
|---|---|---|---|
|
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
|
2025 | Article | 161 |
|
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
|
2023 | Meeting Abstract | 11 |
|
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
|
2023 | Meeting Abstract | 72 |